Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms

Giulia Mearini, Christina Gedicke, Saskia Schlossarek, Christian C. Witt, Elisabeth Krämer, Peirang Cao, Marcelo D. Gomes, Stewart H. Lecker, Siegfried Labeit, Monte Willis, Thomas Eschenhagen, Lucie Carrier

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Aims Familial hypertrophic cardiomyopathy (FHC) is frequently caused by cardiac myosin-binding protein C (cMyBP-C) gene mutations, which should result in C-terminal truncated mutants. However, truncated mutants were not detected in myocardial tissue of FHC patients and were rapidly degraded by the ubiquitin-proteasome system (UPS) after gene transfer in cardiac myocytes. Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C. Methods and resultsHuman wild-type (WT) and truncated (M7t, resulting from a human mutation) cMyBP-C species were co-immunoprecipitated with atrogin-1 after adenoviral overexpression in cardiac myocytes, and WT-cMyBP-C was identified as an interaction partner of MuRF1 by yeast two-hybrid screens. Overexpression of atrogin-1 in cardiac myocytes decreased the protein level of M7t-cMyBP-C by 80 and left WT-cMyBP-C level unaffected. This was rescued by proteasome inhibition. In contrast, overexpression of MuRF1 in cardiac myocytes not only reduced the protein level of WT- and M7t-cMyBP-C by >60, but also the level of myosin heavy chains (MHCs) by >40, which were not rescued by proteasome inhibition. Both exogenous cMyBP-C and endogenous MHC mRNA levels were markedly reduced by MuRF1 overexpression. Similar to cardiac myocytes, MuRF1-overexpressing (TG) mice exhibited 40 lower levels of MHC mRNAs and proteins. Protein levels of cMyBP-C were 29 higher in MuRF1 knockout and 34 lower in TG than in WT, without a corresponding change in mRNA levels. Conclusion These data suggest that atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of MHC.

Original languageEnglish (US)
Pages (from-to)357-366
Number of pages10
JournalCardiovascular Research
Volume85
Issue number2
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Cardiac Myosins
Fingers
Muscles
Cardiac Myocytes
Myosin Heavy Chains
Proteins
Proteasome Endopeptidase Complex
Familial Hypertrophic Cardiomyopathy
Ubiquitin-Protein Ligases
Ubiquitin
Messenger RNA
myosin-binding protein C
Mutation
Fungal Proteins
Genes
Myocardium

Keywords

  • Atrogin-1
  • E3 ubiquitin ligase
  • MuRF1
  • Myosin-binding protein C
  • Sarcomere

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Mearini, G., Gedicke, C., Schlossarek, S., Witt, C. C., Krämer, E., Cao, P., ... Carrier, L. (2010). Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovascular Research, 85(2), 357-366. https://doi.org/10.1093/cvr/cvp348

Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. / Mearini, Giulia; Gedicke, Christina; Schlossarek, Saskia; Witt, Christian C.; Krämer, Elisabeth; Cao, Peirang; Gomes, Marcelo D.; Lecker, Stewart H.; Labeit, Siegfried; Willis, Monte; Eschenhagen, Thomas; Carrier, Lucie.

In: Cardiovascular Research, Vol. 85, No. 2, 01.01.2010, p. 357-366.

Research output: Contribution to journalArticle

Mearini, G, Gedicke, C, Schlossarek, S, Witt, CC, Krämer, E, Cao, P, Gomes, MD, Lecker, SH, Labeit, S, Willis, M, Eschenhagen, T & Carrier, L 2010, 'Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms', Cardiovascular Research, vol. 85, no. 2, pp. 357-366. https://doi.org/10.1093/cvr/cvp348
Mearini G, Gedicke C, Schlossarek S, Witt CC, Krämer E, Cao P et al. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovascular Research. 2010 Jan 1;85(2):357-366. https://doi.org/10.1093/cvr/cvp348
Mearini, Giulia ; Gedicke, Christina ; Schlossarek, Saskia ; Witt, Christian C. ; Krämer, Elisabeth ; Cao, Peirang ; Gomes, Marcelo D. ; Lecker, Stewart H. ; Labeit, Siegfried ; Willis, Monte ; Eschenhagen, Thomas ; Carrier, Lucie. / Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. In: Cardiovascular Research. 2010 ; Vol. 85, No. 2. pp. 357-366.
@article{1fbad961267d48b1b00bef2506f436ba,
title = "Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms",
abstract = "Aims Familial hypertrophic cardiomyopathy (FHC) is frequently caused by cardiac myosin-binding protein C (cMyBP-C) gene mutations, which should result in C-terminal truncated mutants. However, truncated mutants were not detected in myocardial tissue of FHC patients and were rapidly degraded by the ubiquitin-proteasome system (UPS) after gene transfer in cardiac myocytes. Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C. Methods and resultsHuman wild-type (WT) and truncated (M7t, resulting from a human mutation) cMyBP-C species were co-immunoprecipitated with atrogin-1 after adenoviral overexpression in cardiac myocytes, and WT-cMyBP-C was identified as an interaction partner of MuRF1 by yeast two-hybrid screens. Overexpression of atrogin-1 in cardiac myocytes decreased the protein level of M7t-cMyBP-C by 80 and left WT-cMyBP-C level unaffected. This was rescued by proteasome inhibition. In contrast, overexpression of MuRF1 in cardiac myocytes not only reduced the protein level of WT- and M7t-cMyBP-C by >60, but also the level of myosin heavy chains (MHCs) by >40, which were not rescued by proteasome inhibition. Both exogenous cMyBP-C and endogenous MHC mRNA levels were markedly reduced by MuRF1 overexpression. Similar to cardiac myocytes, MuRF1-overexpressing (TG) mice exhibited 40 lower levels of MHC mRNAs and proteins. Protein levels of cMyBP-C were 29 higher in MuRF1 knockout and 34 lower in TG than in WT, without a corresponding change in mRNA levels. Conclusion These data suggest that atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of MHC.",
keywords = "Atrogin-1, E3 ubiquitin ligase, MuRF1, Myosin-binding protein C, Sarcomere",
author = "Giulia Mearini and Christina Gedicke and Saskia Schlossarek and Witt, {Christian C.} and Elisabeth Kr{\"a}mer and Peirang Cao and Gomes, {Marcelo D.} and Lecker, {Stewart H.} and Siegfried Labeit and Monte Willis and Thomas Eschenhagen and Lucie Carrier",
year = "2010",
month = "1",
day = "1",
doi = "10.1093/cvr/cvp348",
language = "English (US)",
volume = "85",
pages = "357--366",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms

AU - Mearini, Giulia

AU - Gedicke, Christina

AU - Schlossarek, Saskia

AU - Witt, Christian C.

AU - Krämer, Elisabeth

AU - Cao, Peirang

AU - Gomes, Marcelo D.

AU - Lecker, Stewart H.

AU - Labeit, Siegfried

AU - Willis, Monte

AU - Eschenhagen, Thomas

AU - Carrier, Lucie

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Aims Familial hypertrophic cardiomyopathy (FHC) is frequently caused by cardiac myosin-binding protein C (cMyBP-C) gene mutations, which should result in C-terminal truncated mutants. However, truncated mutants were not detected in myocardial tissue of FHC patients and were rapidly degraded by the ubiquitin-proteasome system (UPS) after gene transfer in cardiac myocytes. Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C. Methods and resultsHuman wild-type (WT) and truncated (M7t, resulting from a human mutation) cMyBP-C species were co-immunoprecipitated with atrogin-1 after adenoviral overexpression in cardiac myocytes, and WT-cMyBP-C was identified as an interaction partner of MuRF1 by yeast two-hybrid screens. Overexpression of atrogin-1 in cardiac myocytes decreased the protein level of M7t-cMyBP-C by 80 and left WT-cMyBP-C level unaffected. This was rescued by proteasome inhibition. In contrast, overexpression of MuRF1 in cardiac myocytes not only reduced the protein level of WT- and M7t-cMyBP-C by >60, but also the level of myosin heavy chains (MHCs) by >40, which were not rescued by proteasome inhibition. Both exogenous cMyBP-C and endogenous MHC mRNA levels were markedly reduced by MuRF1 overexpression. Similar to cardiac myocytes, MuRF1-overexpressing (TG) mice exhibited 40 lower levels of MHC mRNAs and proteins. Protein levels of cMyBP-C were 29 higher in MuRF1 knockout and 34 lower in TG than in WT, without a corresponding change in mRNA levels. Conclusion These data suggest that atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of MHC.

AB - Aims Familial hypertrophic cardiomyopathy (FHC) is frequently caused by cardiac myosin-binding protein C (cMyBP-C) gene mutations, which should result in C-terminal truncated mutants. However, truncated mutants were not detected in myocardial tissue of FHC patients and were rapidly degraded by the ubiquitin-proteasome system (UPS) after gene transfer in cardiac myocytes. Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C. Methods and resultsHuman wild-type (WT) and truncated (M7t, resulting from a human mutation) cMyBP-C species were co-immunoprecipitated with atrogin-1 after adenoviral overexpression in cardiac myocytes, and WT-cMyBP-C was identified as an interaction partner of MuRF1 by yeast two-hybrid screens. Overexpression of atrogin-1 in cardiac myocytes decreased the protein level of M7t-cMyBP-C by 80 and left WT-cMyBP-C level unaffected. This was rescued by proteasome inhibition. In contrast, overexpression of MuRF1 in cardiac myocytes not only reduced the protein level of WT- and M7t-cMyBP-C by >60, but also the level of myosin heavy chains (MHCs) by >40, which were not rescued by proteasome inhibition. Both exogenous cMyBP-C and endogenous MHC mRNA levels were markedly reduced by MuRF1 overexpression. Similar to cardiac myocytes, MuRF1-overexpressing (TG) mice exhibited 40 lower levels of MHC mRNAs and proteins. Protein levels of cMyBP-C were 29 higher in MuRF1 knockout and 34 lower in TG than in WT, without a corresponding change in mRNA levels. Conclusion These data suggest that atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of MHC.

KW - Atrogin-1

KW - E3 ubiquitin ligase

KW - MuRF1

KW - Myosin-binding protein C

KW - Sarcomere

UR - http://www.scopus.com/inward/record.url?scp=72949105996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949105996&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvp348

DO - 10.1093/cvr/cvp348

M3 - Article

C2 - 19850579

AN - SCOPUS:72949105996

VL - 85

SP - 357

EP - 366

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 2

ER -